Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 18, 2009Cornea

The Ocular Surface in Glaucoma

View Full Paper
Ask AI
Bookmark
Share

Authors

CBChristophe Baudouin

Discussion

Loading...

Member takes

Overview

Review demonstrates that benzalkonium chloride causes ocular surface toxicity in patients with glaucoma, suggesting preservative-free therapies improve tolerability and treatment adherence.

Key Points

  • To review the effects of preservatives on the ocular surface and evaluate how preserved eyedrop formulations influence clinical outcomes in glaucoma patients.
  • Literature review summarizing findings from in vitro human cell culture, animal models, and clinical studies on topical antiglaucoma preservatives, primarily benzalkonium chloride.
  • Benzalkonium chloride exerts toxic effects on corneal and conjunctival epithelia even at low concentrations, compromising tear film quality and volume.
  • Switching to preservative-free antiglaucoma medications significantly decreases adverse ocular events, including burning, stinging, and dry eye symptoms, improving patient adherence.

Cite This Study

Christophe Baudouin (2009) studied this question.

synapsesocial.com/papers/6aa7bdb33cfa9073c49f13a8https://doi.org/10.1097/ico.0b013e3181ae8402
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacokinetics, efficacy and safety profiles of preserved and preservative‐free tafluprost in healthy volunteers2008 · 56 citations
  2. 2Travoprost 0.004% With and Without Benzalkonium Chloride: A Comparison of Safety and Efficacy2007 · 66 citations